TABLE 3.
Subjects with AEs, by body system
| Type of AE | No. of subjects (%) receivinga:
|
|||
|---|---|---|---|---|
| Daptomycin
|
Control | |||
| 4 mg/kg q24h for 7 days | 6 mg/kg q24h for 7 days | 8 mg/kg q24h for 14 days | ||
| Any event | 3 (50) | 3 (50) | 6 (100) | 5 (83) |
| Gastrointestinal | 0 | 0 | 5 (83) | 2 (33) |
| Skin | 0 | 0 | 0 | 3 (50) |
| Nervous system | 1 (17) | 1 (17) | 1 (17) | 1 (17) |
| Laboratory investi- gations | 1 (17) | 0 | 1 (17) | 1 (17) |
| Administration site | 0 | 0 | 4 (67) | 0 |
| Infections | 1 (17) | 0 | 0 | 1 (17) |
| Otherb | 0 | 2 (33) | 2 (33) | 0 |
a
The total number of subjects in each group was six. Values are numbers of subjects who experienced an event at least once.
b
Other body systems each reported once included respiratory, renal, and general disorders and complications from surgical procedures.